---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-002979"
form_type: "8-K"
ticker: "SYRE"
cik: "0001636282"
company_name: "Spyre Therapeutics, Inc."
filed_at: "2023-01-06T23:59:59+00:00"
generated_at: "2026-06-20T18:49:51.734003+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Aeglea BioTherapeutics COO Leslie Sloan departs Jan 5, 2023; receives severance package

## Summary
- COO Leslie Sloan departed Jan 5, 2023; departure not tied to legal or compliance matters.
- Severance includes $435,000 salary continuation (12 months), $174,000 lump-sum bonus, and 12 months COBRA coverage.
- Unvested stock options accelerate vesting for an additional 12 months beyond separation date.
- No successor COO has been announced.

## SEC filing metadata
- accession: 0001193125-23-002979
- form_type: 8-K
- ticker: SYRE
- cik: 0001636282
- company_name: Spyre Therapeutics, Inc.
- filed_at: 2023-01-06T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1636282/000119312523002979/0001193125-23-002979-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1636282/000119312523002979/d380211d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-002979
- JSON: https://secwatch.observer/filing/0001193125-23-002979.json
- Plain text: https://secwatch.observer/filing/0001193125-23-002979.txt

## Key facts
- Executive change
  Leslie Sloan departed as Chief Operating Officer at Spyre Therapeutics, Inc..
  - Action: will no longer serve as
  - Role: Chief Operating Officer
  source text: Effective January 5, 2023 (the “Separation Date”), Leslie Sloan will no longer serve as Chief Operating Officer of Aeglea BioTherapeutics, Inc. (the “Company”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1636282/000119312523002979/0001193125-23-002979-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.